GLP-1 Coverage in 2027: What Self-Funded Employers Should Do

Most self-funded employers should keep GLP-1 coverage for diabetes and move weight-loss coverage to a managed-access model in 2027, rather than drop it entirely or leave it open. The cost pressure is real: among employers that cover GLP-1s for weight loss, the drugs averaged 11.4% of total annual claims in 2026, up from 6.9% in 2023, according to IFEBP survey data. Only 36% of employers cover them for weight loss, and that share did not move last year.

How Much Do GLP-1 Drugs Cost Employer Health Plans?

For employers that cover them for weight loss, GLP-1s are now one of the largest single drivers of plan spend. The impact grows every year as more members start and stay on therapy.

• GLP-1s averaged 11.4% of total annual claims at covering employers in 2026, per IFEBP data reported by Insurance Business.
• That share was 6.9% in 2023, so it has grown by about two-thirds in three years.
• Marsh estimates rising GLP-1 use adds a full percentage point to 2027 health cost trend (Fierce Healthcare).
• List prices for brand GLP-1s run roughly $1,000 or more a month before rebates.
• Members often stay on therapy long term, so the cost repeats every year.

Why the cost hits self-funded plans harder

Self-funded employers pay claims directly, so every new GLP-1 member shows up in plan cost within months. Fully insured groups feel it at renewal instead.

• Pharmacy claims flow through immediately with no carrier smoothing.
• Rebates from the PBM may offset part of the cost, but timing and pass-through vary.
• Stop-loss usually responds to large individual claims, not steady pharmacy spend.
• Utilization can jump quickly once employees learn the drugs are covered.
• Budgeting needs a utilization forecast, not just last year’s pharmacy spend.

Why utilization keeps climbing

More members qualify, more conditions are approved, and members stay on therapy longer. Each factor adds to plan spend on its own.

• GLP-1s are now used beyond diabetes, including cardiovascular disease and sleep apnea indications.
• Public awareness drives requests from members who never asked before.
• Long-term use means this year’s members are usually next year’s members too.
• Supply has improved, removing a barrier that once slowed adoption.
• New oral and next-generation versions may expand demand further.

What Coverage Options Do Employers Have for 2027?

There are four practical paths, and most fall between the extremes. The right choice depends on workforce, budget, and how much you compete for talent on benefits.

• Full coverage for both diabetes and weight loss, with standard pharmacy cost-sharing.
• Managed access, covering weight loss with prior authorization, BMI thresholds, and program requirements.
• Diabetes-only coverage, excluding weight-loss indications.
• No GLP-1 coverage for weight loss, sometimes paired with a discounted cash-pay option.
• Some employers add a time limit or require continued progress to keep coverage.

What dropping coverage really costs

Cutting GLP-1s saves money on the pharmacy line, but it can cost you elsewhere. Some employers are now finding that out in recruiting.

• Some large employers ended weight-loss GLP-1 coverage for 2027, according to Insurance Business.
• Candidates currently covered by their employer may see your plan as a step down.
• Members who stop therapy may regain weight and develop costlier conditions later.
• Mid-year changes create communication and morale problems.
• Any change needs a clear explanation, not just an announcement.

GLP-1 Coverage Options Compared

How Does a Managed-Access GLP-1 Program Work?

Managed access keeps coverage but adds clinical and behavioral guardrails. It aims to cover the members most likely to benefit, and to keep them engaged.

• Prior authorization confirms diagnosis and medical need before the first fill.
• BMI and comorbidity criteria focus coverage on members with the highest health risk.
• Enrollment in a lifestyle or coaching program can be a condition of coverage.
• Reauthorization after six or twelve months requires documented progress.
• Preferred-drug rules steer members to the agents with the best net cost.

Questions to ask your PBM before adopting managed access

The PBM will run the program, so its terms decide whether it works. Get answers in writing before you change the plan.

• What prior authorization criteria will you apply, and can we customize them?
• How are rebates on GLP-1s passed through to the plan?
• What does the lifestyle program cost, and who pays for it?
• What reporting will we get on utilization, adherence, and outcomes?
• How quickly can we change criteria if cost or utilization moves?

How to measure whether managed access is working

Set the metrics before launch, so you can adjust criteria with real data instead of anecdotes.

• Track GLP-1 spend as a share of total plan cost each quarter.
• Monitor approval and denial rates under the new criteria.
• Watch adherence and persistence, since stopping early wastes the spend.
• Measure lifestyle program enrollment and completion.
• Review diabetes and cardiovascular claims trends over time.

How Should Self-Funded Employers Protect Against GLP-1 Costs?

Plan design is only half the answer. Funding, stop-loss, and PBM terms decide how much of the GLP-1 cost you actually absorb.

• Review whether your specific stop-loss attachment point still fits your claim pattern.
• Check stop-loss contracts for any pharmacy or specialty drug exclusions.
• Model GLP-1 utilization growth separately when you set the 2027 budget.
• Confirm rebates flow to the plan, not just to the PBM.
• Revisit your funding model as part of a broader employee benefits strategy.

Why fiduciary process matters here

Coverage decisions for a self-funded plan are fiduciary choices under ERISA. A documented process protects the people who make them.

• ERISA plans are overseen by the Department of Labor’s EBSA.
• Record the cost data, options considered, and reasons for the final decision.
• Apply coverage criteria consistently to avoid discrimination claims.
• Review vendor fees and rebate arrangements as part of fiduciary monitoring.
• Update the plan document and summary plan description when coverage changes.

Fully insured employers have fewer levers

If your plan is fully insured, the carrier sets most GLP-1 rules. Your choice is usually between the carrier’s coverage options at renewal.

• Ask which GLP-1 coverage riders or exclusions the carrier offers for 2027.
• Compare the premium difference between covering and excluding weight-loss use.
• Consider whether level-funding would give you more control.
• Review how the carrier applies prior authorization today.
• Plan communications early, since carrier changes often arrive late in the year.

How Are Employees Paying for GLP-1s Outside the Plan?

Many employees already use cash-pay options when their plan does not cover weight loss. Those options shape how much a coverage cut actually hurts.

• Manufacturer direct-to-consumer programs offer lower monthly cash prices for some GLP-1s.
• Federal cash-pay platforms and discount cards now list several GLP-1 medications.
• Cash-pay discounts usually do not count toward deductibles or out-of-pocket maximums.
• Our guide to whether Wegovy is covered by insurance explains the member side.
• Some employers contribute to an HSA or lifestyle account instead of covering the drug directly.

How GLP-1 coverage fits your broader benefits budget

GLP-1 decisions should not be made in isolation. They affect your total health trend, your contribution strategy, and how competitive your plan looks.

• Start with the full picture in our employee benefits cost per employee benchmarks.
• Fold the GLP-1 decision into your 2027 health benefits renewal playbook.
• Model the cost of each coverage option over three years, not one.
• Factor in potential savings from fewer diabetes and cardiovascular complications.
• Compare your choice with what competing employers in your industry offer.

How Should Employers Communicate a GLP-1 Change?

Early and plainly. Employees accept change better when they understand why it is happening and what support remains.

• Announce changes before open enrollment, not inside the enrollment packet.
• Explain the cost data in simple terms, such as the share of plan spend going to GLP-1s.
• Describe the new criteria and how to qualify, step by step.
• Offer transition time for members already on therapy.
• Point employees to lifestyle programs and other support that stays in place.

What employees should hear from you

A clear message reduces confusion and complaints. Keep it short, specific, and honest about the trade-offs.

• Why the plan is changing and what it costs the plan today.
• Exactly who still qualifies and what steps they need to take.
• How long current members have before new criteria apply.
• What support programs remain available to everyone.
• Where to find help, including your open enrollment resources.